drugset / Trial / NCT02189109

The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma

NCT02189109 ↗

Phase 1 Completed 11 enrolled NuvOx LLC The Alfred · collab
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy. NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.

Timeline

Start
2014-05
Primary completion
2017-08-31
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PERFLENAPENT Small molecule 0.05 ml Intravenous
Subject PERFLENAPENT Small molecule 0.1 ml Intravenous
Subject PERFLENAPENT Small molecule 0.17 ml Intravenous

Indications